| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1010428317692231 |
| P698 | PubMed publication ID | 28618958 |
| P2093 | author name string | Christian Trautwein | |
| Ulf P Neumann | |||
| Tom Luedde | |||
| Christoph Roderburg | |||
| Sven H Loosen | |||
| P2860 | cites work | Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer | Q21245710 |
| MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily | Q24317134 | ||
| Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers | Q24603754 | ||
| Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer | Q24609577 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma | Q24627680 | ||
| MicroRNA miR-155 is a biomarker of early pancreatic neoplasia | Q24649254 | ||
| MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions | Q26769953 | ||
| Prognostic Value of SPARC in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis | Q26770931 | ||
| Prognostic and predictive markers in pancreatic adenocarcinoma | Q26771965 | ||
| Circulating RNAs as new biomarkers for detecting pancreatic cancer | Q26801191 | ||
| Long noncoding RNAs: past, present, and future | Q26991873 | ||
| Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer | Q27851614 | ||
| Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis | Q27853290 | ||
| Identification of Novel Genes Coding for Small Expressed RNAs | Q27860917 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. | Q27863396 | ||
| MicroRNA expression profiles classify human cancers | Q28032481 | ||
| Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer | Q28273473 | ||
| MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis | Q28300240 | ||
| Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes | Q28307762 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| EMT and dissemination precede pancreatic tumor formation | Q29615854 | ||
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Serum Biomarker Panels for the Detection of Pancreatic Cancer | Q30499531 | ||
| Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. | Q33238550 | ||
| MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions | Q33525784 | ||
| Pathology and Molecular Genetics of Pancreatic Neoplasms | Q33581119 | ||
| MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival | Q33748264 | ||
| Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma | Q34045939 | ||
| Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. | Q34177223 | ||
| Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer | Q34241079 | ||
| Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer | Q34384632 | ||
| Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma | Q39566515 | ||
| Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology | Q39742359 | ||
| MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease | Q39950193 | ||
| Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer | Q40267587 | ||
| High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients | Q40434420 | ||
| KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas | Q40554859 | ||
| MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer | Q41769515 | ||
| MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens | Q42105717 | ||
| Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial | Q44299542 | ||
| Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression | Q44431342 | ||
| The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. | Q45122012 | ||
| Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma | Q46076287 | ||
| Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes | Q46373824 | ||
| The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies | Q46761472 | ||
| Survival and prognostic factors of unresectable pancreatic cancer | Q46838044 | ||
| Analyzing S100A6 expression in endoscopic ultrasonography-guided fine-needle aspiration specimens: a promising diagnostic method of pancreatic cancer | Q47233666 | ||
| Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray | Q47620397 | ||
| Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Q50921728 | ||
| Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer | Q53204525 | ||
| S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples | Q53334864 | ||
| High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival | Q53620792 | ||
| PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma | Q53724719 | ||
| MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm | Q54247736 | ||
| Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. | Q54629144 | ||
| Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. | Q54657752 | ||
| Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines | Q57767569 | ||
| The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms | Q34471577 | ||
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. | Q34557866 | ||
| Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer | Q34577084 | ||
| Expression profiling identifies microRNA signature in pancreatic cancer | Q34588109 | ||
| MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma | Q34604367 | ||
| Alternative Processing of the U2 Small Nuclear RNA Produces a 19–22nt Fragment with Relevance for the Detection of Non-Small Cell Lung Cancer in Human Serum | Q34635648 | ||
| Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial | Q34646032 | ||
| A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile | Q34664680 | ||
| Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer | Q34669394 | ||
| MicroRNAs accurately identify cancer tissue origin | Q34764379 | ||
| Diagnostic performance of serum macrophage inhibitory cytokine-1 in pancreatic cancer: a meta-analysis and meta-regression analysis | Q35110096 | ||
| Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis | Q35192310 | ||
| Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis | Q35375731 | ||
| Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer | Q35551996 | ||
| Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions | Q35887807 | ||
| Whole genomes redefine the mutational landscape of pancreatic cancer | Q35911034 | ||
| A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy | Q35946922 | ||
| Performance status assessment in cancer patients. An inter-observer variability study | Q35976499 | ||
| Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. | Q36009614 | ||
| PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma | Q36412915 | ||
| Serum Osteopontin and Tissue Inhibitor of Metalloproteinase 1 as Diagnostic and Prognostic Biomarkers for Pancreatic Adenocarcinoma | Q36622740 | ||
| Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance | Q36695184 | ||
| Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival | Q36747210 | ||
| Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer | Q36750985 | ||
| Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoi | Q36822149 | ||
| Modelling prognostic factors in advanced pancreatic cancer | Q36882688 | ||
| SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients | Q37162084 | ||
| Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. | Q37367504 | ||
| Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival | Q37562530 | ||
| Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview | Q37824829 | ||
| SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial | Q38385490 | ||
| microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis | Q38498940 | ||
| Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells | Q39094301 | ||
| Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer | Q39257961 | ||
| P433 | issue | 6 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1010428317692231 | |
| P577 | publication date | 2017-06-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Current and future biomarkers for pancreatic adenocarcinoma | |
| P478 | volume | 39 |
| Q90643838 | A cellular and bioinformatics analysis of the SENP1 SUMO isopeptidase in pancreatic cancer |
| Q64250552 | Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed? |
| Q64099112 | Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis |
| Q92817642 | Biosensors for early diagnosis of pancreatic cancer: a review |
| Q93121764 | Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network |
| Q64994232 | Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. |
| Q47808198 | Duodenal invasion by pancreatic adenocarcinoma: MDCT diagnosis of an aggressive imaging phenotype and its clinical implications |
| Q47749335 | Extrapancreatic perineural invasion in pancreatic adenocarcinoma |
| Q47561604 | Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma |
| Q58702365 | Identification and characterization of transforming growth factor beta-induced in circulating tumor cell subline from pancreatic cancer cell line |
| Q58605578 | Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer |
| Q92714897 | Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells |
| Q91584525 | PACAP and PAC1 receptor expression in pancreatic ductal carcinoma |
| Q92258093 | Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer |
| Q49793590 | Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression |
| Q47427120 | Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation |
| Q52666355 | Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges |
| Q92328358 | The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma |
| Q58780532 | The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer |
| Q59794360 | lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma |
Search more.